Ghost Tree Capital, LLC
Q1 2014 13F-HR Holdings
Net value change ($000)
+5,879
(3.6%)
New positions
28
Sold out positions
26
Turnover %
96.3%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q4 2013
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| AMAG | 3,716 | NEW |
| FLAMEL TECHNOLOGIES SA | 3,054 | 316.1% |
| CHELSEA THERAPEUTICS INTL LT | 2,868 | 645.9% |
| INTERCEPT PHARMACEUTICALS, INC. | 2,638 | NEW |
| MMSI | 2,503 | NEW |
| FURIEX PHARMA INC | 2,393 | NEW |
| EW | 2,225 | NEW |
| ISRG | 2,190 | NEW |
| ALGN | 1,813 | NEW |
| Histogen Inc. | 1,790 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| GILD | -10,139 | -100.0% |
| CUBIST PHARMACEUTICALS INC | -3,444 | -100.0% |
| MAZOR ROBOTICS LTD SPONSORED ADS | -3,416 | -100.0% |
| HEARTWARE INTERNATIONAL INC | -3,343 | -100.0% |
| ZBH | -3,262 | -100.0% |
| SPECTRANETICS CORP COM | -2,859 | -65.3% |
| QUIDEL CORP /DE/ | -2,626 | -100.0% |
| Aceragen, Inc. | -2,547 | -100.0% |
| SAGENT PHARMACEUTICALS INC | -2,538 | -100.0% |
| GenMark Diagnostics, Inc. | -2,525 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
71,413
(42.4% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|